# US 10,870,663 B2 · Compounds useful in HIV therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,870,663 B2
- Document ID: US10870663B2
- Status: Granted
- Kind: B2
- Application number: 16/897,351
- Filed: 2020-06-10
- Published: 2020-09-24
- Granted: 2020-12-22
- Earliest claimed: 2018-11-30
- Assignees: GlaxoSmithKline Intellectual Property Development Limited
- Applicants: GlaxoSmithKline Intellectual Property Development Limited; The University of North Carolina at Chapel Hill; ViiV Healthcare Company
- Inventors: Richard M Dunham; David Margolis; Vincent Wing-Fai Tai; Jun Tang
- Web page: https://patentgrep.com/patent/US10870663B2

## CPC

- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61P 31/18: for HIV
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates a compound of the formula: a pharmaceutically acceptable salt thereof, compositions thereof, and methods of therapeutic treatment using the same.

## Claims

### Claim 1

A compound having the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A salt according to claim 1, wherein the salt is present as a hydrochloride salt.

### Claim 3 (depends on 2)

The salt according to claim 2, wherein the hydrochloride salt is a dihydrochloride salt.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

### Claim 5 (depends on 4)

The composition according to claim 4, wherein said composition is adapted for parenteral administration.

### Claim 6 (depends on 1)

A method of depleting latent HIV infected cells comprising administering to a subject a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

A method of treating an HIV infection in a subject comprising administering to the subject a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 8

A compound having the structure:

### Claim 9 (depends on 8)

A pharmaceutical composition comprising a compound according to claim 8, and a pharmaceutically acceptable excipient.

### Claim 10 (depends on 9)

The composition according to claim 9, wherein said composition is adapted for parenteral administration.

### Claim 11 (depends on 8)

A method of depleting latent HIV infected cells comprising administering to a subject a compound of claim 8.

### Claim 12 (depends on 8)

A method of treating an HIV infection in a subject comprising administering to the subject a compound of claim 8.